A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

Last updated: April 8, 2025
Sponsor: Karuna Therapeutics
Overall Status: Completed

Phase

3

Condition

Psychosis

Tourette's Syndrome

Schizotypal Personality Disorder (Spd)

Treatment

Placebo

Xanomeline and Trospium Chloride Capsules

Clinical Study ID

NCT05919823
CN012-0063
ZL-2701-001
  • Ages 18-65
  • All Genders

Study Summary

A Phase 3, Multicenter, Two-part Study with a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects with DSM-5 Schizophrenia

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Subject is Chinese national, aged 18 to 65 years, inclusive, at screening.

  2. Subject is capable of providing written informed consent.

  3. Subject has a primary diagnosis of schizophrenia established by a comprehensivepsychiatric evaluation based on the DSM-5 and MINI.

  4. Subject is experiencing an acute exacerbation or relapse of psychotic symptoms, withonset less than 2 months before screening.

  5. The subject requires hospitalization for this acute exacerbation or relapse ofpsychotic symptoms at screen.

  6. If already an inpatient at screening, hospitalization has to be ≤2 weeks forthe current exacerbation at the time of screening.

  7. PANSS total score between 80 and 120,inclusive, with a scores of ≥4 (moderate orgreater) for ≥2 of the following Positive Scale (P) items:

  8. Item 1 (P1; delusions)

  9. Item 2 (P2; conceptual disorganization)

  10. Item 3 (P3; hallucinatory behavior)

  11. Item 6 (P6; suspiciousness/persecution)

  12. Subjects with no change (improvement) in PANSS total score between screening andbaseline (Day -1) of more than 20%.

  13. Subject has a CGI-S score of ≥4 at screening and baseline (Day -1) visits.

  14. Subject will have been off lithium therapy for at least 2 weeks before baseline andfree of all oral antipsychotic medications for at least 5 half-lives or 1 week,whichever is longer, before baseline (Day -1).

  15. Subjects taking a long-acting injectable antipsychotic could not have received adose of medication for at least 12 weeks (24 weeks for INVEGA TRINZA®) beforebaseline visit (Day -1).

  16. Subject is able to be confined to an inpatient setting for the duration of the 5-week double-blind part of the study, follow instructions, and comply with theprotocol requirements.

  17. Body mass index of 18 to 40 kg/m2, inclusive.

  18. Subject resides in a stable living situation and is anticipated to return to thatsame stable living situation after discharge, in the opinion of the investigator.

  19. Subject has an identified reliable informant. An informant is needed at thescreening and baseline visits as well as at the end of the study for relevantassessments (site staff may act as informant while the subject is an inpatient). Aninformant may not be necessary if the subject has been a patient of the investigatorfor ≥1 year.

  20. Women of childbearing potential (WOCBP) or men whose sexual partners are WOCBP mustbe willing and able to adhere to the contraception guidelines.

Exclusion

Exclusion Criteria:

  1. Any primary DSM-5 disorder other than schizophrenia within 12 months beforescreening (confirmed using MINI version 7.0.2 at screening).

  2. Subjects who are newly diagnosed or are experiencing their first treated episode ofschizophrenia.

  3. History or presence of clinically significant cardiovascular, pulmonary, hepatic,renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,neurologic, or oncologic disease or any other condition that, in the opinion of theinvestigator, would jeopardize the safety of the subject or the validity of thestudy results.

  4. Subjects with human immunodeficiency virus (HIV), cirrhosis, biliary ductabnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections basedon either medical history or liver function test results.

  5. History or high risk of urinary retention, gastric retention, or narrow-angleglaucoma.

  6. History of irritable bowel syndrome (with or without constipation) or seriousconstipation requiring treatment within the last 6 months.

  7. Risk for suicidal behavior during the study as determined by the investigator'sclinical assessment and C-SSRS.

  8. Clinically significant abnormal findings on the physical examination, medicalhistory, electrocardiogram, or clinical laboratory results at screening that, in theopinion of the investigator, would jeopardize the safety of the subject or thevalidity of the study results.

  9. Subjects are receiving or have recently received (within 5 half-lives or 1 week,whichever is longer, before baseline [Day -1]) oral antipsychotic medications;monoamine oxidase inhibitors; anticonvulsants (e.g., lamotrigine, valproate);tricyclic antidepressants (e.g., imipramine, desipramine); selective serotoninreuptake inhibitors; or any other psychoactive medications except for as-neededanxiolytics (e.g., lorazepam, chloral hydrate).

  10. Subjects are receiving or have recently received (within 1 week before baseline [Day -1]) metformin.

  11. Pregnant, lactating, or less than 3 months postpartum.

  12. In the opinion of the investigator and/or Sponsor, subject is unsuitable forenrollment in the study or subject has any finding that, in the view of theinvestigator and/or Sponsor, may compromise the safety of the subject or affecthis/her ability to adhere to the protocol visit schedule or fulfill visitrequirements.

  13. Subject has had psychiatric hospitalization(s) for more than 30 days (cumulative)during the 90 days before screening.

  14. Subject has a history of treatment resistance to schizophrenia medications definedas failure to respond to 2 adequate courses of pharmacotherapy (a minimum of 4 weeksat an adequate dose per the label) or has required clozapine within the last 12months.

  15. Subjects with prior exposure to KarXT.

  16. Subjects who experienced any significant adverse effects due to trospium chloride.

  17. Participation in another clinical study within 3 months before screening in whichthe subject received an experimental or investigational drug agent.

  18. Significant risk of violent or destructive behavior.

Study Design

Total Participants: 202
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
May 29, 2023
Estimated Completion Date:
December 09, 2024

Connect with a study center

  • Anhui Mental Health Center

    Hefei, Anhui 230022
    China

    Site Not Available

  • Wuhu Hospital of Beijing Anding Hospital

    Wuhu, Anhui 241000
    China

    Site Not Available

  • Beijing Anding Hospital Capital Medical University

    Beijing, Beijing 100035
    China

    Site Not Available

  • Peking University Sixth Hospital

    Beijing, Beijing 100083
    China

    Site Not Available

  • Beijing HuiLongGuan Hospital

    Changping, Beijing 100096
    China

    Site Not Available

  • Chongqing 11th People's Hospital

    Chongqing, Chongqing 400047
    China

    Site Not Available

  • Chongqing Mental Health Center

    Jiangbei, Chongqing 401147
    China

    Site Not Available

  • The Affiliated Brain Hospital of Guangzhou Medical University

    Guanzhou, Guangdong 510370
    China

    Site Not Available

  • The Sixth People's Hosptial of Hebei Province

    Baoding, Hebei 071051
    China

    Site Not Available

  • The First Hospital of Hebei Medical University

    Shijia Zhuang, Hebei 050030
    China

    Site Not Available

  • Daqing City Third Hospital

    Daqing, Heilongjiang 163161
    China

    Site Not Available

  • Zhumadian Second People's Hospital

    Zhumadian, Henan 463001
    China

    Site Not Available

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei 430064
    China

    Site Not Available

  • Wuhan Mental Health Center

    Wuhan, Hubei 430000
    China

    Site Not Available

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan 410011
    China

    Site Not Available

  • Wuxi Mental Health Center

    Wuxi, Jiangsu 214151
    China

    Site Not Available

  • Jiangxi Mental Health Center

    Nanchang, Jiangxi 330027
    China

    Site Not Available

  • Mental Health Center of Xi'an City

    Xi'an, Shaanxi 710061
    China

    Site Not Available

  • Shandong Mental Health Center

    Jinan, Shandong 250014
    China

    Site Not Available

  • Shandong Daizhuang Hospital

    Jining, Shandong 272009
    China

    Site Not Available

  • Shanghai Mental Health Center

    Shanghai, Shanghai 200032
    China

    Site Not Available

  • The Fourth People's Hospital of Chengdu

    Chengdu, Sichuan 610036
    China

    Site Not Available

  • Guangyuan Mental Health Center

    Guangyuan, Sichuan 628033
    China

    Site Not Available

  • Tianjin Anding Hospital

    Tianjin, Tianjin 300382
    China

    Site Not Available

  • Urumqi Fourth People's Hospital

    Ürümqi, Xinjiang 830002
    China

    Site Not Available

  • Hangzhou Seventh People's Hospital

    Hangzhou, Zhejiang 310013
    China

    Site Not Available

  • HuZhou Third Municipal Hospital

    Huzhou, Zhejiang 313028
    China

    Site Not Available

  • Ningbo Kangning Hospital

    Ningbo, Zhejiang 315002
    China

    Site Not Available

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang 325015
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.